Sionna Therapeutics reports Q4 EPS ($3.38) vs. ($3.93) last year

“2024 was an excellent year for Sionna including strong clinical execution across multiple programs. Encouraging interim Phase 1 data for SION-719 and SION-451, our highly potent nucleotide-binding domain 1 stabilizers, showed that both candidates were generally well tolerated and achieved target exposures-reinforcing their potential to deliver meaningful clinical benefits for people with CF,” said Mike Cloonan, CEO. “Building on this momentum, we successfully completed an upsized IPO, a significant milestone that extends our cash runway into 2028 and provides financial and strategic flexibility. 2025 is off to a strong start with the consummation of the IPO and the progression of the Phase 1 single ascending dose and multiple ascending dose trials for SION-719 and SION-451. We look forward to announcing topline data in the first half of this year and initiating our Phase 2a proof-of-concept trial and the combination MAD Phase 1 program later this year.”